(0.70%) 5 118.00 points
(0.10%) 38 328 points
(0.97%) 17 738 points
(0.65%) $84.11
(-3.79%) $1.576
(0.76%) $2 360.40
(1.05%) $27.64
(0.52%) $925.30
(0.05%) $0.932
(0.47%) $11.00
(-0.01%) $0.799
(-0.19%) $92.00
@ $108.31
Issued: 24 Apr 2024 @ 14:00
Return: -0.81%
Previous signal: Apr 22 - 14:50
Previous signal:
Return: -0.64 %
Live Chart Being Loaded With Signals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally...
Stats | |
---|---|
Today's Volume | 419 039 |
Average Volume | 608 035 |
Market Cap | 6.70B |
EPS | $0 ( 2024-02-28 ) |
Next earnings date | ( $4.16 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 17.61 |
ATR14 | $1.830 (1.70%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-05 | Gala Renee D | Sell | 1 736 | Ordinary Shares |
2024-03-06 | Carr Patricia | Sell | 1 236 | Ordinary Shares |
2024-03-06 | Carr Patricia | Sell | 700 | Ordinary Shares |
2024-03-07 | Carr Patricia | Sell | 1 768 | Ordinary Shares |
2024-03-05 | Gala Renee D | Sell | 3 622 | Ordinary Shares |
INSIDER POWER |
---|
43.47 |
Last 96 transactions |
Buy: 357 937 | Sell: 150 837 |
Volume Correlation
Jazz Pharmaceuticals PLC Correlation
10 Most Positive Correlations | |
---|---|
SLVO | 0.91 |
DTSS | 0.903 |
DCRC | 0.887 |
FNWD | 0.875 |
AZTA | 0.874 |
NAKD | 0.873 |
MRNA | 0.866 |
BMRN | 0.864 |
PIXY | 0.861 |
INVA | 0.86 |
10 Most Negative Correlations | |
---|---|
NRDS | -0.922 |
MORF | -0.92 |
HYPR | -0.909 |
MYNA | -0.908 |
SVC | -0.903 |
HAPP | -0.893 |
PETV | -0.891 |
BLBD | -0.889 |
MLTX | -0.889 |
STRL | -0.886 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Jazz Pharmaceuticals PLC Correlation - Currency/Commodity
Jazz Pharmaceuticals PLC Financials
Annual | 2023 |
Revenue: | $3.83B |
Gross Profit: | $2.79B (72.78 %) |
EPS: | $6.55 |
FY | 2023 |
Revenue: | $3.83B |
Gross Profit: | $2.79B (72.78 %) |
EPS: | $6.55 |
FY | 2022 |
Revenue: | $3.66B |
Gross Profit: | $3.12B (85.23 %) |
EPS: | $-3.42 |
FY | 2021 |
Revenue: | $3.09B |
Gross Profit: | $2.65B (85.76 %) |
EPS: | $-5.52 |
Financial Reports:
No articles found.
Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators